Since our data showed PHLPP2 activity correlated with PD-L1 expression in mutant p53-driven cancer cells, the activation/inhibition of PHLPP2 or eIF4E/4EBP1 might be some of the factors that influence response to ICIs, and could be therefore a future direction for research. The gene discussed is TP53; the disease is cancer.